AUSTIN, Texas / Feb 20, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2023, after the market close on Feb. 28, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
Earnings Conference Call Information:
Event: | Natera’s Fourth Quarter and Year-End 2023 Financial Results | |
Date: | Wednesday, Feb. 28, 2024 | |
Time: | 1:30 p.m. PT (4:30 p.m. ET) | |
Live Dial-In:
| 1 (888) 770-7321 (Domestic) | |
Conference ID: | 7684785 | |
Webcast: | ||
A webcast replay will be available at investor.natera.com. | ||
About Natera
Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 180 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.
| Last Trade: | US$237.53 |
| Daily Change: | 6.90 2.99 |
| Daily Volume: | 1,114,714 |
| Market Cap: | US$32.780B |
November 12, 2025 November 06, 2025 October 28, 2025 October 20, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
